Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Fears Realized As Japan Moves To Annual Price Cuts

Executive Summary

Against the protests of the innovative pharma industry, Japan is pushing ahead with an overhaul of its drug reimbursement pricing system that will include a shift to annual price revisions.

You may also be interested in...

Japan Slashes Opdivo Price 50% After Prescriptions Surge

Merck’s Keytruda could see its launch price set lower too after Opdivo’s rapidly rising use in lung cancer triggers maximum statutory price cut.

Pricey New HCV, Cancer Drugs Push Up Japan’s Health Care Costs

Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.

Revised Japan Prices Include Big Cuts For Gilead HCV Drugs

With policy surrounding the regular drug price revision in Japan next month finalized and a list of new tariff prices just released, it has become clear that Gilead is facing sizeable reimbursement reductions for its two big-selling hepatitis C drugs in the country.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts